This upcoming weekend will be marked by my presence at the meeting of the American Academy of Neurology, which is to be held in San Diego. During this event, I’ll be engaged in discussions with experts who are unveiling the opportunities related to the use of GLP-1 class of medications for neurodegenerative conditions. But let’s now turn our attention to today’s news cycle. Early today, an influx of staff reduction announcements were received by a significant number of employees working under the Department of Health and Human Services (HHS) and its auxiliary entities, with potential layoffs calculated to reach around 10,000.
The biotechnology sector witnessed a sharp slump by close to 4% yesterday. Out of the many contributing factors, one that shook investors was the dramatic departure of Peter Marks, the apex authority from FDA supervising vaccine and gene therapy regulations. This drastic market reaction was recorded in an industry that had already been grappling with a sustained fall in valuations. The final tally from the day’s close revealed the Biotechnology Sector ETF Fund (XBI) ended the first quarter by shedding nearly 10% of its value, a steeper fall compared to broader markets and technology stocks.
Yesterday was particularly harsh on pharmaceutical companies involved in the production of vaccines. Unexpected hints of discord with the HHS Secretary, Robert F. Kennedy Jr. embedded within Marks’ resignation letter appears to be a reason for the sharp reactions in the market. Moderna’s shares tanked by 9% while Vaxcyte found its market value shrink by a severe 46%.
Furthermore, the aftermath of Marks’ resignation didn’t spare companies engaged in pioneering work on cell and gene therapies with their shares experiencing sharp declines. Uniqure saw its stock value dropped by around 15% and Neuorgene wasn’t far behind with a decline of about 20%. However, the direct effects of Marks’ stepping down are primarily focused on vaccine oversight, with potential impacts on other biologics remaining elusive.
What’s also floating in uncertainties is the potential fallout within the FDA’s key personnel lineup, along with considerations of who might rise into Marks’ now-empty shoes. Creating more instability, the sprawling cutbacks from the Trump administration on PEPFAR, a global program aimed at AIDS relief, hovers portentously over the impending deployment of Gilead’s promising HIV preventive medication, raising doubts over an initiative that had the potential to save myriad lives.
In clinical trials, Gilead illuminated a positive path with its experimental drug, lenacapavir. The medication, dosed semiannually, demonstrated nearly full-proof defence against infection. Currently seeking regulatory approval, this drug kindled hope by hinting at the possibility of attenuating the lethal infectious disease on global scales.
Preliminary results derived from a new version of the same drug indicate that it may require administration as sparse as once a year. While news like these kindle hope, there are other areas where voids are creating uncertainties. For instance, a fortnight ago, we reported the sudden step-down of Eric Green from his directorial post at the National Human Genome Research Institute located within the NIH.
In the absence of a clear hierarchy, it remains unclear as to who has taken up the mantle to oversee the working avenues of the institute. Notably, the institute was involved in significant projects, aimed at advancing diagnosis and treatment of genetic disorders among large population blocks. While the above constitutes occurrences that expose gaps in the system, there are also situations where authorities have been checked.
A federal legal adjudicator ruled against the FDA in a remarkable verdict yesterday. The ruling came in support of lab associations who claimed that the federal agency had exceeded its authority limits. The subject of the disagreement was the FDA’s intent to exercise control over laboratory-developed tests, which was contested by the labs.
Historically, it has been the FDA’s stance that it possesses the ability to regulate lab-made investigations, positioning them under the medical devices category. Though the agency has held this stance, it has seldom enforced this in the past. However, these developments may not yet be set in stone as the lawmakers have room to appeal the decision.
The post FDA’s Apex Authority Marks Resigns Amidst Market Slump appeared first on Real News Now.
About Author
